Research programme: influenza-A virus H5N1 vaccine - Replikins

Drug Profile

Research programme: influenza-A virus H5N1 vaccine - Replikins

Alternative Names: H5N1 Synthetic Replikins Vaccine

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Replikins
  • Class Influenza A virus H5N1 vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Influenza A virus H5N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (Intranasal, Aerosol)
  • 31 Dec 2009 Preclinical trials in Influenza A virus H5N1 subtype infections (prevention) in USA (Intranasal)
  • 31 Dec 2009 Preclinical pharmacodynamics data from in avian Influenza-A virus H5N1 infections published Replikins
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top